Emavusertib

Generic Name: Emavusertib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₅N_₇O_₅

CAS Number: 1801344-14-8

Unique Ingredient Identifier: MH5DMF9JKY

Clinical Trials

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Metastatic Colorectal Adenocarcinoma
Stage III Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography

First Posted Date: 2024-11-20

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT06696768

Locations: 🇺🇸
Yale University Cancer Center LAO, New Haven, Connecticut, United States

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1

Recruiting

Conditions: Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2024-06-03

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT06439836

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1

Suspended

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Nab-paclitaxel
Procedure: Positron Emission Tomography
Procedure: X-Ray Imaging

First Posted Date: 2023-01-17

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT05685602

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 24 locations

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Phase 1

Suspended

Conditions: Melanoma Metastatic in the Brain

Interventions: Drug: CA-4948
Drug: Pembrolizumab

First Posted Date: 2022-12-30

Last Posted Date: 2025-04-04

Lead Sponsor: University of Florida

Target Recruit Count: 29

Registration Number: NCT05669352

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Phase 1

Recruiting

Conditions: Gastric Cancer
Stomach Cancer
Gastroesophageal Junction Cancer
Esophagus Cancer
Esophageal Cancer

Interventions: Drug: CA-4948
Biological: Nivolumab
Biological: Pembrolizumab
Drug: Trastuzumab
Drug: mFOLFOX7

First Posted Date: 2022-01-11

Last Posted Date: 2025-01-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT05187182

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Anemia

Interventions: Drug: CA-4948

First Posted Date: 2022-01-05

Last Posted Date: 2024-08-13

Lead Sponsor: University of Leipzig

Target Recruit Count: 38

Registration Number: NCT05178342

Locations: 🇩🇪
Charité Berlin - Campus Benjamin Franklin, Med. Klinik m. S. Hämatologie, Onkologie, Tumorimmunologie, Berlin, Germany
🇩🇪
Carl-Thiem-Klinikum Cottbus gGmbH, 2. Med. Klinik, Cottbus, Germany
🇩🇪
Gemeinschaftspraxis Dr. Jacobasch Dresden, Hämatologie Onkologie, Dresden, Germany

and more 12 locations

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Drug: Venetoclax
Drug: Emavusertib

First Posted Date: 2020-02-20

Last Posted Date: 2024-07-26

Lead Sponsor: Curis, Inc.

Target Recruit Count: 366

Registration Number: NCT04278768

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 27 locations

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Phase 1

Recruiting

Conditions: Relapsed Primary Central Nervous System Lymphoma
Relapsed Hematologic Malignancy
Refractory Primary Central Nervous System Lymphoma
Refractory Hematologic Malignancy

Interventions: Drug: Emavusertib
Drug: Ibrutinib

First Posted Date: 2017-11-01

Last Posted Date: 2025-01-24

Lead Sponsor: Curis, Inc.

Target Recruit Count: 152

Registration Number: NCT03328078

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy